Rutgers Project ECHO
Substance Use Disorder (SUD) ECHO

Provided by Rutgers Robert Wood Johnson Medical School

Target Audience

This activity is designed for healthcare providers connected to primary care, including physicians, mid-levels, nurses, social workers, addiction specialists, and pharmacists throughout New Jersey who treat substance use disorder and mental health and conduct medication-assisted treatment.

Learning Objectives

After participating in ECHO, participants should be better able to:

- Describe the screening tools useful for management of substance use disorders in primary care settings
- Identify pharmacologic treatment modalities available for patients with substance use disorders
- Identify non-pharmacologic treatment modalities available for patients with substance use disorders
- Self-regulate attitudes and beliefs about patient presentations to provide safe and effective management of patients with substance use disorders
- Identify appropriate community resources for patients with substance use disorders

Rutgers Project ECHO Planning Committee

Eric Jahn, MD
Kathy Dodsworth-Rugani, PhD
Mary Bridgeman, PharmD
Amy Fisher, MHA
Brittany Sullivan, MSPH
Brian Reid, MHA
Suzanne Spernal, DNP
Ashley Figueroa, MPA
Ruben Nanez
Michelle Rupe, MSW

SUD ECHO Session Leaders

- Petros Levounis, MD, MA, Professor and Chair, Department of Psychiatry, Rutgers New Jersey Medical School
- Rashi Aggarwal, MD, Associate Professor and Director, Psychiatry Residency Training Program Rutgers New Jersey Medical School
- Geoffrey Talis, MD, Psychiatry Resident, Rutgers New Jersey Medical School
- Clement Chen, PharmD, BCPS, Clinical Pharmacist/Academic Detailer, Rutgers New Jersey Medical School
- Lynda Bascelli, MD, Addiction Medicine, Cooper University Health Care
- Brian Colangelo, LCSW, CADC, Addiction Medicine, Cooper University Health Care

Accreditation

JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

CME

Rutgers Biomedical and Health Sciences designates this live activity a maximum of 12 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Each session is designated for a maximum of 1 *AMA PRA Category 1 Credits*™.

CNE

This activity is awarded 12 contact hours. (60-minute CH) Each session is awarded a maximum of 1 contact hours.

Nurses should only claim those contact hours actually spent participating in the activity.

CPE

This application-based activity qualifies for 12 contact hours of continuing pharmacy education credit. Each session qualifies for a maximum of 1 contact hours of continuing pharmacy education credit.

Pharmacists should claim only those contact hours actually spent participating in this activity.

Social Workers (The New Jersey Board of Social Work Examiners): This program is approved for social work continuing education hours by Rutgers University Behavioral Health Care in accordance with New Jersey administrative code 13:44G-6.4 and recognized by The New Jersey Board of Social Work Examiners. This program is approved for 12 continuing education hours.

Method of Participation

In order to receive CE credit, participants must register for the ECHO and complete the evaluation and credit request at the conclusion of each session. Participants will receive one statement of credit from Rutgers Biomedical and Health Sciences at the conclusion of the series.

Pharmacists: Your official record of ACPE credit will be generated though the CPE Monitor System on a monthly basis. Your NABP e-Profile ID and date of birth will be collected through the evaluation and credit request. Please note that you must complete the evaluation and credit request for each session by the requested date. Under ACPE Policy, Rutgers Biomedical and Health Sciences (RBHS) will not be able to report your activity completion to CPE Monitor if your NABP e-Profile ID and date of birth are reported to and received by RBHS more than 60 days following the activity.

Peer Review Statement

In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, RBHS has resolved all potential and real conflicts of interest through content review by a non-conflicted, qualified reviewer. This activity was peer-reviewed for relevance, accuracy of content and balance of presentation by the steering committee.

Disclosure Disclaimer

In accordance with the disclosure policies of RBHS and to conform with Joint Accreditation requirements and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.

Financial Disclosure Declarations

The following session leaders have no relevant financial relationships to disclose:

Petros Levounis, MD
Rashi Aggarwal, MD
Geoffrey Talis, MD
Clement Chen, PharmD
Lynda Bascelli, MD
Brian Colangelo, LCSW

The following planning committee members have relevant financial relationships to disclose:

Eric Jahn, MD – Stock shareholder (directly purchased): Proctor & Gamble, Johnson & Johnson

Kathy Dodsworth-Rugani, PhD – Stock shareholder (directly purchased): Johnson & Johnson, Pfizer

Mary Bridgeman, PharmD, – Member, Speakers Bureau: AstraZeneca

The following planning committee members have no relevant financial relationships to disclose:

Ashley Figueroa, MPA
Brittany Sullivan, MSPH
Brian Reid, MHA
Michelle Rupe, MSW

Ruben Nanez
Suzanne Spernal, DNP

Amy Fisher, MHA

Off-label/Investigational Use Disclosure

Speakers are required to disclose discussion of off-label/investigational uses of commercial products. These disclosures will be made to the audience at the time of the activity.